Journal
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
Volume 36, Issue 2-3, Pages 91-97Publisher
HUMANA PRESS INC
DOI: 10.1007/s12016-008-8101-2
Keywords
Malignancy; Thrombosis; Catastrophic anti-phospholipid syndrome; CAPS; Asherson's syndrome; Anti-phospholipid syndrome
Categories
Ask authors/readers for more resources
The catastrophic anti-phospholipid (Asherson's) syndrome (CAPS) is characterised by the rapid chronological development of fulminant thrombotic complications that predominantly affect small vessels and differs from the anti-phospholipid syndrome in its accelerated systemic involvement leading to multi-organic failure. Malignancy may play a pathogenic role in patients with CAPS, whereas infections are more important as triggering factors in patients without malignancies. CAPS patients with malignancies are generally older than CAPS patients without malignancies; they generally have the worst prognosis of the entire CAPS cohort.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available